Coco Enterprises LLC Sells 1,736 Shares of Pfizer Inc. (NYSE:PFE)

Posted by on Mar 16th, 2023

Coco Enterprises LLC decreased its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 12.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,877 shares of the biopharmaceutical company’s stock after selling 1,736 shares during the period. Pfizer comprises approximately 0.5% of Coco Enterprises LLC’s investment portfolio, making the stock its 26th biggest holding. Coco Enterprises LLC’s holdings in Pfizer were worth $525,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. RB Capital Management LLC raised its position in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. increased its position in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank increased its position in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares in the last quarter. Ergoteles LLC increased its position in shares of Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares in the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.

Pfizer Stock Up 1.0 %

Shares of Pfizer stock opened at $40.28 on Thursday. Pfizer Inc. has a 52-week low of $39.23 and a 52-week high of $56.32. The company has a 50 day moving average of $43.67 and a 200 day moving average of $46.11. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $226.34 billion, a P/E ratio of 7.35, a P/E/G ratio of 1.31 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. During the same quarter in the previous year, the firm earned $1.08 earnings per share. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price objective for the company in a research report on Tuesday, February 7th. Barclays lowered their price target on Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 1st. StockNews.com started coverage on Pfizer in a research note on Thursday. They issued a “buy” rating on the stock. Jefferies Financial Group started coverage on Pfizer in a research note on Monday, March 6th. They issued a “hold” rating and a $43.00 price target on the stock. Finally, SVB Leerink lowered their price target on Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 1st. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $50.75.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.